According to the Company, a phase 2 trial will begin enrollment by the end of 2025. The Food and Drug Administration (FDA) has granted Orphan Drug designation to BRC-002 for the treatment of complex ...
The European Commission has granted EU orphan drug designation to Synerkine Pharma BV’s SK-01 to treat complex regional pain syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results